Investors took off exposure to Exact Sciences (NASDAQ:EXAS) in September ahead of a key update to colon cancer screening and that decision appears to have been the right one given that guidelines announced this month failed to include Exact Sciences' Cologuard.

In the following slideshow, you'll learn why this update to guidelines was important for Exact Sciences and the risks that its investors continue to face.

 

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.